ARVO 2023: Analysis of vision loss from GATHER clinical program

Article

Dr Carl Danzig, MD, FASRS, spoke at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.

Dr Carl Danzig, MD, FASRS, spoke at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.

Video transcript

Editor’s note: This transcript has been edited for clarity.

Carl Danzig, MD, FASRS:

Hi, I'm Carl Danzig and I'm happy to be here at ARVO. I'm happy to talk about the post hoc analysis regarding vision loss in the GATHER program.

This is exciting new data that I'm presenting, and what we saw in the GATHER – in this analysis regarding the GATHER program was a decreased rate of 10, 15 and 20 letter losers in patients receiving ACP 2/mg versus sham. Well, we also saw in a separate analysis is a 56% risk reduction of persistent vision loss in patients receiving treatment versus sham. Persistent vision loss, decrease of 15 letters on two consecutive visits or more. And for the first time, what we saw was a correlation between vision loss and GA growth.

This is exciting because what we saw in this study was that patients with increased vision loss had increased GA progression. Patients in the ACP 2/mg treatment arm had decreased rate of GA progression, independent of whether or not they had vision loss. We see the potential with continued treatment of ACB 2/mg of decreasing the rate of vision loss in this patient population. We find this very exciting.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.